UK pharmaceutical company GSK plc (NYSE: GSK) has entered into a licensing agreement with Chimagen Biosciences, securing all global rights to CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE). GSK will pay an upfront fee of USD 300 million and is committed to making success-based development and commercial milestone payments totaling USD 550 million. The total transaction value of up to USD 850 million is subject to customary closing conditions.
CMG1A46 is an IgG-like molecule with high affinity for CD19 and CD20 positive B cells and low affinity for CD3, which may reduce the toxicities commonly associated with TCEs. The drug candidate is currently undergoing Phase I clinical studies for leukemia and lymphoma in the US and China. GSK plans to develop and commercialize CMG1A46, focusing on B cell-driven autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the potential to expand into other related autoimmune diseases.- Flcube.com
